Related Experiment Video
Updated: Jun 17, 2026

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease
Yousuf Khalifa1, Allison R Loh, Nisha R Acharya
1F.I. Proctor Foundation, University of California, San Francisco, California 94143-0412, USA.
Purpose:
To describe the use of fluocinolone acetonide implants (Retisert) in Vogt-Koyanagi-Harada disease (VKH).
Design:
Interventional case series.
Methods:
Retrospective review of medical records.
Results:
Two patients with VKH requiring high-dose systemic corticosteroid therapy to control their inflammation and bilateral serous retinal detachments received bilateral fluocinolone acetonide implants. Upon tapering of systemic corticosteroids, one patient had recurrent serous retinal detachments and the other patient's anterior chamber and vitreous inflammation returned.
Conclusions:
The authors' experience with fluocinolone acetonide implants in VKH has been mixed with an inability to fully taper off of systemic corticosteroids.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Ophthalmic Drug Delivery Systems
Diabetic Retinopathy
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

